Clinical presentation and management of patients with circulating anticoagulants

  • Alison Moliterno
  • William R. Bell
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 386)


Acquired hemophilia is characterized by the development of antibodies to coagulation proteins. Although these inhibitors are rare, they pose serious threats to health as a result of their ability to produce spontaneous hemorrhage. As these inhibitors occur infrequently, epidemiological analyses of their patterns of occurrence, details of clinical presentations, and practical management of acute hemorrhage are difficult to gather. In an effort to augment the clinical data base, we reviewed the records of 26 patients treated at our institution from 1980 to 1993.


Factor VIII Caproic Acid Acute Hemorrhage Spontaneous Hemorrhage Coagulation Protein 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    . Green, D., and Lechner, K., A survey of 215 non-hemophilic patients with inhibitors to Factor VIII, Thromb Haemost. 45: 200 (1981).PubMedGoogle Scholar
  2. 2.
    . Lottenberg, R., Kentro, T.B., and Kitchens, C.S., Acquired hemophilia. A natural history study of 16 patients with Factor VIII inhibitors receiving little or no therapy, Arch Intern Med. 147: 1077 (1987).PubMedCrossRefGoogle Scholar
  3. 3.
    . Soriano, R.M., Matthews, J.M., and Guerado-Parra, E., Acquired hemophilia and rheumatoid arthritis, Br J. Rheumatol. 26: 381 (1987).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1995

Authors and Affiliations

  • Alison Moliterno
    • 1
  • William R. Bell
    • 1
  1. 1.Division of HematologyJohns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations